Avisa Diagnostics Inc FOGCF

Avisa Diagnostics Inc. is a clinical-stage medical device company. The Company is engaged in the development of the Allora BreathTest (ABT), a drug/device biomarker technology platform. The Allora BreathTest (ABT) is an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of bacterial load. ABT enables the ultra-rapid detection of virulent bacterial pathogens, detecting and monitoring bacterial load after the patient inhales or ingests its drug substrates via its own delivery systems. Its ABT portfolio includes Post-Covid-19 Bronchiectasis, Develo, Ventilator-Associated Pneumonia (VAP), Chronic Obstructive Pulmonary Disease (COPD), Community-Acquired, Pneumonia (CAP), Cystic Fibrosis, Tuberculosis, Aspergillus Fungus and Clostridium Difficile (C. diff).

GREY:FOGCF - Post by User

Avisa Diagnostics Inc > 1 SHARE FOR EVERY 15 YOU HAVE OF NEW COMPANY .

<< Previous

Bullboard Posts

Next >>

Post by frewil11on Feb 09, 2021 12:27pm

208 Views

Post# 32513733

1 SHARE FOR EVERY 15 YOU HAVE OF NEW COMPANY .

The Consolidation

Immediately prior to the completion of the Transaction, it is a condition that the Company consolidate its issued and outstanding share capital on the basis of fifteen (15) pre-consolidation FogChain Shares for one (1) post-consolidation FogChain Share (the " Consolidation "). The FogChain Shares to be issued to Avisa in connection with the Transaction will be issued on a post-Consolidation basis.

The FogChain Shares issued in connection with the Transaction may be subject to escrow conditions and/or resale restrictions as required by applicable securities laws and the policies of the CSE.

<< Previous

Bullboard Posts

Next >>

First Helium advances winter drilling program with Leduc Anomaly test well